Union Health Minister Shri Jagat Prakash Nadda Launches Indigenously Manufactured Tetanus & Adult Diphtheria (Td) Vaccine at Central Research Institute, Himachal Pradesh

1. At a Glance

• Indigenously manufactured Tetanus & Adult Diphtheria (Td) vaccine launched on 21 Feb 2026 at Central Research Institute (CRI), Kasauli, Himachal Pradesh by Union Health Minister J.P. Nadda [S1][S2].
• Marks India's formal TT-to-Td switch under the Universal Immunization Programme (UIP), aligning with WHO's 2006 recommendation for dual tetanus + diphtheria protection in older age groups [S3][S4].
• Significant for UPSC as a convergence of Atmanirbhar Bharat in health, public-sector vaccine manufacturing revival, and maternal/adolescent immunization policy.

2. Why in the News

• 21 Feb 2026 — J.P. Nadda launched the indigenous Td vaccine at CRI Kasauli; CRI committed to supply 55 lakh doses to UIP by April 2026 [S2].
• Minister stated India has achieved ~99% vaccine coverage under UIP, calling Td introduction a "milestone in public health infrastructure" [S2].

3. Background & Evolution

• CRI Kasauli founded 3 May 1905 as the Pasteur Institute of India for rabies prophylaxis; today a premier public-sector vaccine institute under DGHS, Ministry of Health & Family Welfare [S5].
• WHO (2006) advised replacement of Tetanus Toxoid (TT) with Td since adult diphtheria immunity wanes; many adolescent/adult diphtheria cases reported globally [S3][S4].
• NTAGI (National Technical Advisory Group on Immunization) recommended TT→Td switch in India across all age groups including pregnant women [S4].
• India had already begun phased rollout of imported Td; the 2026 launch operationalises indigenous manufacture at CRI [S2][S4].
• CRI completed Test Licence, waivers for preclinical & Phase I–III trials, Marketing Authorisation, commercial manufacturing, and CDL Kasauli batch release prior to launch [S2].

4. Core Static Facts

• Vaccine: Td (Tetanus toxoid + reduced-dose adult Diphtheria toxoid) — replaces standalone TT in UIP [S3][S4].
• Manufacturer: Central Research Institute (CRI), Kasauli, Solan district, Himachal Pradesh [S2][S5].
• Parent body: Directorate General of Health Services, Ministry of Health & Family Welfare [S5].
• Programme: Universal Immunization Programme (UIP), launched 1985; one of the world's largest public-health programmes.
• UIP Td schedule (unchanged from TT): given at 10 years and 16 years of age, and two doses during pregnancy (Td1, Td2) [S4].
• Initial supply commitment: 55 lakh doses by April 2026 [S2].
• Regulatory batch release: Central Drugs Laboratory (CDL), Kasauli [S2].
• WHO transition guidance: issued 2006 [S3].

5. Multi-Dimensional Analysis

Scientific / Technological - Td uses reduced antigen (lower-case "d") diphtheria toxoid to avoid hyperreactivity in adults — biologically distinct from paediatric DPT [S3][S4]. - CRI secured clinical trial waivers based on WHO prequalification class equivalence — illustrates the CDSCO–NTAGI pathway for established antigens [S2].

Administrative / Governance - Vertical integration: manufacture (CRI) → quality release (CDL Kasauli) → distribution (UIP/MoHFW) — all within one ministry [S2]. - Demonstrates revival of public-sector vaccine units (CRI, BCG Guindy, Pasteur Coonoor) after years of suspension over GMP issues.

Economic / Atmanirbhar Bharat - Reduces dependence on private/imported Td; advances self-reliance in essential biologics [S2]. - Saves UIP procurement cost — Td earlier imported from a limited pool of WHO-prequalified suppliers.

Social / Public Health - Protects adolescents (10y, 16y boosters) and pregnant women — directly supports maternal & neonatal tetanus elimination (MNTE) status India achieved in 2015 [S4]. - Closes the adult diphtheria immunity gap evidenced by sporadic outbreaks among unvaccinated/older cohorts.

Federal - UIP funded centrally; delivery via state immunization officers, ANMs, ASHAs — a classic Centre-State cooperative-federal scheme.

6. Recent Developments

• 21 Feb 2026: Indigenous Td vaccine launched at CRI Kasauli; 55 lakh-dose commitment by April 2026 [S2].
• 20 Feb 2026 (advisory): PIB pre-announcement of launch event [S1].
• India earlier transitioned imported Td into UIP based on NTAGI advice; 2026 marks indigenous-manufacture milestone [S4].

7. Prelims Hooks

• Td vaccine launched 21 February 2026 at CRI, Kasauli (Himachal Pradesh) [S2].
• Td replaces TT in UIP, in line with WHO 2006 recommendation [S3][S4].
• CRI Kasauli established 1905 as Pasteur Institute of India [S5].
• CRI operates under DGHS, MoHFW (NOT ICMR, NOT DBT) [S5].
• Regulatory batch release authority: Central Drugs Laboratory (CDL), Kasauli [S2].
• Body that recommended TT→Td switch: NTAGI [S4].
• UIP Td schedule: 10 years, 16 years, and during pregnancy (2 doses) [S4].
• Initial indigenous supply: 55 lakh doses by April 2026 [S2].
• "d" in Td denotes reduced-dose adult diphtheria toxoid [S3].
• India achieved Maternal & Neonatal Tetanus Elimination status in 2015 (WHO-validated) [S4].
• UIP currently reports ~99% vaccine coverage per MoHFW (2026) [S2].
• CRI obtained waivers for Phase I–III clinical trials for Td [S2].

8. Mains Relevance

• GS-II: Government policies/interventions in Health; Issues relating to development & management of Social Sector — Health.
• GS-III: Science & Technology — indigenisation; Achievements of Indians in S&T.
• Plausible question stems: 1. "Indigenisation of vaccine manufacturing is central to India's health self-reliance." Discuss with reference to recent initiatives. (GS-III) 2. Examine the policy rationale and public-health implications of replacing TT with Td under UIP. (GS-II) 3. Evaluate the role of public-sector vaccine institutes (CRI Kasauli, BCG Guindy, Pasteur Coonoor) in India's immunization architecture. (GS-II/III)

9. Related Topics to Study Next

• Universal Immunization Programme (UIP) & Mission Indradhanush — parent programme delivering Td.
• NTAGI — apex immunization advisory body; its mandate and composition.
• CDSCO & Central Drugs Laboratory, Kasauli — vaccine regulation in India.
• Maternal & Neonatal Tetanus Elimination (MNTE) 2015 — India's WHO-validated milestone.
• PM-ABHIM & National Health Mission — public-health infrastructure funding.
• Atmanirbhar Bharat (Pharma & Biotech) — PLI Scheme for bulk drugs/vaccines.
• WHO Expanded Programme on Immunization (EPI) — global framework Td flows from.
• Indigenous vaccines pipeline: Covaxin, DengiAll, Cervavac (HPV), R21 malaria — comparison.

10. Common Errors / Trap Areas

• Td ≠ Tdap: Td has no acellular pertussis; Tdap does. UIP uses Td, not Tdap [S3].
• CRI Kasauli is under MoHFW/DGHS, NOT under ICMR or DBT [S5].
• WHO recommended TT→Td switch in 2006, not in 2026; 2026 is only the Indian indigenous-manufacture launch [S3].
• The "d" (lower case) signals reduced antigen adult dose — confusing with paediatric DPT's "D".
• Td replaces TT only in UIP; DPT/Penta for infants remains unchanged.
• 55 lakh doses is CRI's supply commitment by April 2026, not annual UIP demand (which is far higher) [S2].

11. Sources

• [S1] Union Health Minister to Launch Td Vaccine at CRI Kasauli on 21 Feb 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2230793 — (tier: 1)
• [S2] Union Health Minister Shri J.P. Nadda Launches Indigenously Manufactured Td Vaccine at CRI, HP — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2231147 — (tier: 1)
• [S3] WHO recommendation on Td (via Td Operational Guidelines, NHM/MoHFW) — https://nhm.gov.in/New_Updates_2018/NHM_Components/Immunization/Guildelines_for_immunization/Td_vaccine_operational_guidelines.pdf — (tier: 1)
• [S4] Td Vaccine FAQs, NHM/MoHFW — https://nhm.gov.in/New_Updates_2018/NHM_Components/Immunization/Guildelines_for_immunization/Td_vaccine_FAQs.pdf — (tier: 1)
• [S5] CRI Kasauli 119th Foundation Day, PIB — https://pib.gov.in/PressReleasePage.aspx?PRID=1922842 — (tier: 1)